These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30807561)

  • 1. New guideline-sanctioned and emerging interventions for pancreatic cancer.
    Bekaii-Saab T
    Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):7-9. PubMed ID: 30807561
    [No Abstract]   [Full Text] [Related]  

  • 2. A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
    Bekaii-Saab T
    Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):5-7. PubMed ID: 30807560
    [No Abstract]   [Full Text] [Related]  

  • 3. Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
    Yu K
    Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):9-10. PubMed ID: 30807562
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges of pancreatic cancer chemotherapy in the COVID-19 era.
    Vidra R; Bodea R; Mercea V; Nemes A
    J Gastrointestin Liver Dis; 2020 Jun; 29(2):273-275. PubMed ID: 32531001
    [No Abstract]   [Full Text] [Related]  

  • 5. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRINOX goes adjuvant.
    Romero D
    Nat Rev Clin Oncol; 2019 Mar; 16(3):145. PubMed ID: 30659285
    [No Abstract]   [Full Text] [Related]  

  • 7. Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
    Lima CMSR
    Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):3-5. PubMed ID: 30807559
    [No Abstract]   [Full Text] [Related]  

  • 8. What options are available for refractory pancreatic cancer?
    Choi M; Kim R; Saif MW
    JOP; 2012 Mar; 13(2):163-5. PubMed ID: 22406591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
    Surinach A; Phung T; Abdul-Rahim O; Khushman M
    Curr Oncol; 2020 Apr; 27(2):e222-e225. PubMed ID: 32489272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
    Du J; Gu J; Li J
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
    Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH
    Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
    Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
    Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
    Raphael MJ; Raskin W; Habbous S; Tai X; Beca J; Dai WF; Arias J; Forbes L; Gavura S; Biagi JJ; Earle CC; Chan KKW
    JAMA Netw Open; 2021 Nov; 4(11):e2133388. PubMed ID: 34779846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
    Girardi DM; Faria LDBB; Teixeira MC; Costa FP; Hoff PMG; Fernandes GS
    J Gastrointest Cancer; 2019 Dec; 50(4):860-866. PubMed ID: 30175393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
    Sarvepalli D; Rashid MU; Rahman AU; Ullah W; Hussain I; Hasan B; Jehanzeb S; Khan AK; Jain AG; Khetpal N; Ahmad S
    Crit Rev Oncog; 2019; 24(2):199-212. PubMed ID: 31679214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
    Zhang SH; Liu GF; Li XF; Liu L; Yu SN
    J Cell Physiol; 2018 Apr; 233(4):3352-3374. PubMed ID: 28926090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer.
    Kayahan N; Karaca M; Satış H; Yapar D; Özet A
    Turk J Med Sci; 2021 Aug; 51(4):1727-1732. PubMed ID: 33315355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.